https://www.thebodypro.com/category/dolutegravir-tivicay

Dolutegravir (Tivicay)

The Latest

Dolutegravir More Effective Than Efavirenz at Achieving Viral Suppression During Late-Term Pregnancy, New Study Shows Img
Conference Coverage

Dolutegravir More Effective Than Efavirenz at Achieving Viral Suppression During Late-Term Pregnancy, New Study Shows

Unlike some previous studies that focused on early pregnancy, this study showed no associated congenital disabilities with either drug.

De-Simplifying Single-Tablet Regimens for HIV Treatment Img

De-Simplifying Single-Tablet Regimens for HIV Treatment

A Canadian study of this cost-saving approach found high acceptance of de-simplification among people already on a single-tablet regimen, and even higher rates among people who were just initiating single-tablet treatment.

Are Integrase Inhibitors Linked to Weight Gain? An Evidence Review Img

Are Integrase Inhibitors Linked to Weight Gain? An Evidence Review

Integrase inhibitors are associated with greater increases in body weight than other antiretrovirals, especially among women and black people. But it's unclear whether these changes are clinically significant.

Dual Maintenance Therapy With Dolutegravir + Rilpivirine Img
News Analysis

Dual Maintenance Therapy With Dolutegravir + Rilpivirine

In clinical trials called Sword 1 and Sword 2, researchers testing a combination of dolutegravir/rilpivirine (Juluca) found it to be effective and tolerable.

GEMINI and the Rise of Two-Drug HIV Therapy: A Top HIV Clinical Development of 2018 Img

GEMINI and the Rise of Two-Drug HIV Therapy: A Top HIV Clinical Development of 2018

The concept of a three-drug minimum for HIV therapy is rooted in a sequentialism that emerged with the dawning of antiretroviral treatment: one drug = nothing; two drugs = meh; three drugs = bingo! Over the years, in an effort to avoid peskier antire...

Debate Over Dolutegravir in Early Pregnancy: A Top HIV Clinical Development of 2018 Img

Debate Over Dolutegravir in Early Pregnancy: A Top HIV Clinical Development of 2018

In 2018, the same year we learned that a two-drug initial HIV treatment regimen featuring dolutegravir (Tivicay, DTG) was viable for many of our patients, we also got a much-less-welcome dolutegravir (Tivicay, DTG)-related surprise. Early in the year...

Italian Study Explores Dual Drug Regimens as Maintenance Treatment Img

Italian Study Explores Dual Drug Regimens as Maintenance Treatment

Researchers found that around 90% of participants who were switched to a dual drug regimen maintained a suppressed viral load over the course of the study.

Dolutegravir Monotherapy: Still No Longer Recommended in Either Research or Clinical Practice Img
Conference Coverage

Dolutegravir Monotherapy: Still No Longer Recommended in Either Research or Clinical Practice

Although treatment guidelines since 2016 recommend against further research into the use of dolutegravir monotherapy, it was disconcerting to have two oral presentations at AIDS 2018 reporting studies that still continued after the 2016 recommendatio...

Lynne Mofenson, M.D., at AIDS 2018 in Amsterdam, the Netherlands (Credit: Terri Wilder)

Lynne Mofenson, M.D., Explains the Dolutegravir Risks for People With HIV Who Want to Get Pregnant

New information was presented at the 2018 International AIDS Conference in Amsterdam about babies born with neural tube defects to women with HIV who started a regimen with dolutegravir (Tivicay, DTG) and then later got pregnant.

Dolutegravir-Based Two-Drug Regimen Just as Good for HIV Treatment as Three-Drug Therapy, Study Says Img

Dolutegravir-Based Two-Drug Regimen Just as Good for HIV Treatment as Three-Drug Therapy, Study Says

A dolutegravir-based two-drug regimen was non-inferior to the standard three-drug therapy among treatment-naive participants, according to results from the two GEMINI trials presented at the International AIDS Conference in Amsterdam, the Netherlands...